Literature DB >> 10528902

Adjuvant therapy of rectal cancer.

B D Minsky1.   

Abstract

For patients with clinically resectable stage T3 and/or node-positive rectal cancer, adjuvant radiation therapy decreases the rate of local recurrence. The addition of systemic chemotherapy further enhances local control and improves survival. Compared with postoperative therapy, preoperative treatment may have less toxicity and may increase the chance of sphincter preservation. The acute and long-term toxicity of pelvic radiation is related to the technique of delivery. Therefore, appropriate conventional radiation doses and techniques are recommended. Randomized trials comparing preoperative and postoperative combined modality therapy are in progress.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528902

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

Review 1.  Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer.

Authors:  Rolf Sauer
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  Net survival of patients with colorectal cancer: a comparison of two periods.

Authors:  Zdravko Štor; Rok Blagus; Alessandro Tropea; Antonio Biondi
Journal:  Updates Surg       Date:  2019-06-12

3.  An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation.

Authors:  S Cascinu; F Graziano; V Catalano; M P Staccioli; M C Rossi; A M Baldelli; S Barni; A Brenna; S Secondino; P Muretto; G Catalano
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.